Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy

October 19th, 2004

Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy

Abstract:
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation, announced today that Insert is planning with City of Hope Comprehensive Cancer Center a broad-based Phase I clinical trial for Insert's lead drug candidate.

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Arrowhead Research Corporation

Related News Press

Nanomedicine

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024

Announcements

New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024

Single atoms show their true color July 5th, 2024

New method cracked for high-capacity, secure quantum communication July 5th, 2024

Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project